More DCAT Value Chain Insights

In-depth analysis of the critical issues impacting the full spectrum of the pharmaceutical manufacturing value chain.

Three COVID-19 vaccines by Pfizer/BioNTech, Moderna, and J&J have been authorized for emergency use in the US. What are the supply targets for 2021 and beyond, and what manufacturing networks (internal and external) are being used? DCAT Value...

Executive Summary There are a range of benefits in using an integrated supplier to streamline biologic drug development starting in early phase through clinical and commercial stages. Partnering with one supplier that understands how to best...

Which of the new drugs expected to launch in 2021 have blockbuster potential (defined as products with sales of $1 billion or more)? What are revenue projections, and what is the mix between small molecules and biologics? DCAT Value Chain Insights...

Supply-chain vulnerabilities exposed during the COVID-19 pandemic as well as those existing pre-pandemic were behind an executive order signed by President Joe Biden late last month (February 2021) to require a 100-day supply-chain review of four...

Reshoring manufacturing, including drug manufacturing, has gained policy momentum in the US and EU stemming in part from supply-chain vulnerabilities exposed during the COVID-19 pandemic. But will that momentum continue, and how would such policies...

Medicines for Europe, which represents generic-drug and biosimilar manufacturers, is calling on the EU to recognize value-added medicines as a separate group of medicines and with that recognition, to develop specific frameworks for their...

In 2020, the FDA approved or tentatively approved 948 abbreviated new drug applications for generics, including 72 first generics, which was on par with recent years. The COVID-19 pandemic had an impact as more than 660 supplements and 50 original...